Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 761 results for "Victoza"

Novo Nordisk Injection Receives Backing from FDA Panel
Med India

Novo Nordisk wins EU approval for a diabetes combo with billio...

Novo Nordisk ($NVO) picked up European approval for a combination of a long-acting insulin and its own Victoza, pioneering a once-a-day approach to Type 2 diabetes that could bring in blockbuster sales. The drug pairs Tresiba, an insulin analog ... FierceBiotech, 5 hours ago
FDA panel backs Novo Nordisk injection Perth Now, 4 days ago

4 images for Victoza

Pharmafocus, 5 days ago
Bariatric News, 6 days ago
Pharma Letter, 1 month ago
Mercola, 2 months ago
American Banking News

Novo Nordisk's Earnings Rise on Solid Victoza, Levemir Sales

Novo Nordisk ( NVO ) reported second-quarter 2014 earnings of 48 cents per American Depository Receipt (:ADR), higher than the year-ago earnings of 44 cents. In the reported quarter, revenues increased 6% to $3.9 billion year over year. The ...
 Yahoo! Finance1 month ago Novo Nordisk A/S's (NVO) CEO Lars Sørensen on Q2 2014 Results - Earnings Call Transcript  Seeking Alpha1 month ago Novo Nordisk more valuable than GlaxoSmithKline? That's what investors say  FiercePharma1 month ago Zacks Reiterates Neutral Rating for Novo Nordisk A/S (NVO)  American Banking News1 month ago
Pharma Letter

Novo Nordisk Profit Beats Estimates as Victoza Sales Rise

Novo Nordisk A/S (NOVOB) , the world's largest insulin maker, reported a 3.9 percent increase in second-quarter profit, helped by sales of the Victoza diabetes treatment. Net income climbed to 6.99 billion kroner ($1.25 billion) from 6.73 billion ...
 Bloomberg1 month ago Novo Nordisk beats estimates as net profit grows 4%  Pharma Letter1 month ago

Once-Weekly Dulaglutide Is Noninferior to Daily Liraglutide

The investigational once-weekly dulaglutide (Eli Lilly) is noninferior to once-daily liraglutide ( Victoza , Novo Nordisk), providing similar glycated hemoglobin (HbA 1c ) reductions, in adults with type 2 diabetes poorly controlled with metformin, ...
 American Journal of Public Health1 month ago Weekly Dulaglutide Performs Well in Comparison to Daily Liraglutide  Diabetes Health Magazine1 month ago

Novo Nordisk A/S: Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014

7% sales growth in local currencies driven by Levemir® and Victoza® Sales increased by 7% in local currencies and by 1% in Danish kroner to DKK 42.0 billion during the first six months of 2014 compared to the same period in 2013. Sales of modern ...
 EuroInvestor1 month ago Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014  FirstWord Pharma1 month ago Novo Nordisk gains CHMP backing for Tresiba, Victoza combination therapy for diabetes  FirstWord Pharma1 month ago Novo cutting emissions while building capacity at massive Denmark plant  FiercePharmaManufacturing4 weeks ago
MedCity News

Celebrity-endorsed drug ads don't work, says research

Novo Nordisk hired celebrity chef Paula Deen, who has type 2 diabetes and takes to promoting Victoza New research reveals the US system of using celebrity-endorsed drug adverts offer treatments more credibility but not influence when it comes to ...
 Pharmafocus4 weeks ago EU agency recommends approval of Novo's insulin + type 2 diabetes treatment combo  MedCity News1 month ago UPDATE 1-Novo wins EU recommendation for two-in-one diabetes drug  Reuters1 month ago Novo wins EU recommendation for two-in-one diabetes drug  Reuters1 month ago
Reuters UK

Novo finds new way to sell Tresiba in EU while awaiting another shot in U.S.

Xultophy is a combo of Tresiba and Victoza Share Tools Novo Nordisk ($NVO) is hustling to get work done so that it can resubmit its blockbuster hopeful Tresiba to the FDA next year with an eye on getting into the market by 2016, three years ...
 FiercePharma52 minutes ago Novo Nordisk picks diabetes-ridden Mexico for first Ryzodeg launch  FiercePharma2 weeks ago Novo Nordisk aims at US launch of Tresiba in early 2016  The Gulf Today1 month ago Novo says Tresiba trial is ahead of schedule  MedNous1 month ago

Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown

Eli Lilly ($LLY) took another big step toward filing its long-acting insulin peglispro for an approval, racking up some more positive HbA1c Phase III data in a head-to-head showdown with Sanofi's ($SNY) bestselling Lantus. The pharma giant won't ...
 FierceBiotech2 weeks ago FDA approves Eli Lilly's Trulicity to treat type 2 diabetes  FirstWord Pharma10 hours ago UPDATED: FDA hands Eli Lilly a big win, OKs dulaglutide for diabetes  FierceBiotech20 hours ago FDA approves Lilly's Trulicity to treat type 2 diabetes  Pharma Letter6 hours ago
San Francisco Chronicle

Novo coy on Victoza weight loss filing

 Pharma In Focus3 days ago FDA ready to approve weight-loss drugs  San Francisco Chronicle1 week ago Novo Weight Drug Targets Market Where Others Failed  La Repubblica1 week ago Novo Weight-Loss Drug May Crack Market Others Have Missed  BusinessWeek1 week ago
Bariatric News

Victoza injection for obesity recommended by FDA

The panel of Food and Drug Administration advisers has voted 14-1 that Novo Nordisk's Victoza (liraglutide) injectable drug should be approved for patients who are obese or dangerously overweight. The wants the FDA to approve the drug as an obesity ...
 Bariatric News1 week ago Saxenda injection for obesity recommended by FDA panel  Bariatric News6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less